COSCIENS Biopharma Inc T.CSCI

Limitations according to one article:

[prophetoffactz]

Macimorelin is CSCI's test.
Are these issues solvable?

"The other tests suggested by guidelines are the glucagon stimulation test (GST) and the macimorelin test [3]. Macimorelin is a synthetic GH secretagog (GHS) [7] that has the advantage to be orally administered, with few side effects [8]. Unfortunately, very high cost and the potential drug-to-drug interactions limit the use of the test. Moreover, the announcement in August 2022 that macimorelin should be temporarily discontinued in the commercial market of US makes this test less used in clinical practice..."

Once upon a time: the glucagon stimulation test in diagnosing adult GH deficiency - PMC (nih.gov)

[prophetoffactz]

"Unfortunately, very high cost and the potential drug-to-drug interactions limit the use of the test." If Macimorelin was proven as a standalone test eliminating the need for a second test that could justify a premium price. The current pediatric trial is testing that and we will see the results. The dosage has also been doubled in the pediatric trial to 1 mg/kg vs. adult dosing